Core Viewpoint - Morgan Stanley expects a positive reaction in the stock price of MicroPort Scientific Corporation (00853) and reiterates an "Overweight" rating with a target price of HKD 18.2 [1] Group 1: Business Developments - The company has reached a final agreement to merge its Cardiac Rhythm Management (CRM) business with China Medical Technologies-B (02160) [1] - The successful completion of this transaction is anticipated to eliminate significant uncertainties that have been troubling the company [1] Group 2: Financial Position - The company has successfully refinanced its convertible bonds for the CRM business with bank loans at lower interest rates, further strengthening its financial position [1] - This refinancing arrangement is expected to reduce the company's financing costs, supporting its goal of narrowing net losses year-on-year and achieving a net profit target of USD 90 million by fiscal year 2026 [1]